Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.66 |
| ▸ | DRD3 | P35462 | 4/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD5 | P21918 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4067518 | 0.98 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL5336469 | 0.89 | DRD2 (0.57) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL13993807 | 0.82 | DRD2 (0.58) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL27663343 | 0.81 | OPRK1 (0.57) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL3401759 | 0.80 | OPRK1 (0.60) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL20683375 | 0.80 | DRD2 (0.62) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL723832 | 0.80 | DRD2 (0.74) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL30481367 | 0.80 | TAAR1 (0.61) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16942776 | 0.80 | TAAR1 (0.61) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL11653919 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011070585-A1 | PROCESSES FOR PREPARING RIVASTIGMINE, SALTS AND INTERMEDIATES THEREOF | SHODHANA LABORATORIES LIMITED (IN) | 2011-06-16 | — | — | WO | claimed |
| EP-1856036-A1 | AN EFFICIENT METHOD FOR PREPARATION OF (S)-3-[(1-DIMETHYL AMINO)ETHYL]-PHENYL-N-ETHYL-N-METHYL-CARBAMATE | Emcure Pharmaceuticals Limited (IN) | 2007-11-21 | — | — | EP | claimed |
| WO-2006048720-A1 | AN EFFICIENT METHOD FOR PREPARATION OF (S)-3-[(1-DIMETHYL AMINO)ETHYL]-PHENYL-N-ETHYL-N-METHYL-CARBAMATE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2006-05-11 | — | — | WO | claimed |
| WO-2003101917-A2 | A PROCESS FOR THE PREPARATION OF PHENYLCARBAMATES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-12-11 | — | — | WO | claimed |
| CN-112194767-B | Benzoxazine resin containing zwitter-ion group and preparation method and application thereof | 山东大学 | 2021-06-29 | — | — | CN | disclosed |
| CN-112142935-B | Benzoxazine resin containing quaternary ammonium group and preparation method and application thereof | 山东大学 | 2021-06-29 | — | — | CN | disclosed |
| CN-112194767-A | Benzoxazine resin containing zwitter-ion group and preparation method and application thereof | 山东大学 | 2021-01-08 | — | — | CN | disclosed |
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| CN-112142935-A | Benzoxazine resin containing quaternary ammonium group and preparation method and application thereof | 山东大学 | 2020-12-29 | — | — | CN | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
| EP-2582799-B1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| EP-0951284-B1 | PHENYLETHYLAMINE DERIVATIVES | TEVA PHARMA (IL) | 2003-10-08 | — | — | EP | disclosed |
| EP-0951284-A4 | PHENYLETHYLAMINE DERIVATIVES | TEVA PHARMA (IL) | 2002-03-20 | — | — | EP | disclosed |
| EP-0951284-A1 | PHENYLETHYLAMINE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998026775-A1 | PHENYLETHYLAMINE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-06-25 | — | — | WO | disclosed |
| WO-1996002524-A1 | PHENYLCARBAMATE DERIVATIVES SUITABLE TO THE USE AS ANTICHOLINESTERASE SUBSTANCES | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1996-02-01 | — | — | WO | disclosed |
| EP-0150073-B1 | 3,4-DISUBSTITUTED-1,2,5-OXADIAZOLES HAVING HISTAMINE H2-RECEPTOR ANTAGONIST ACTIVITY | Bristol-Myers Squibb Company (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0150073-A1 | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2-receptor antagonist activity | Bristol-Myers Squibb Company (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4507485-A | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity | BRISTOL-MYERS COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | ACHE, SQLE, BCHE | DRD2 677/4885DRD3 917/4885DRD1 623/4885 |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | ACHE, SQLE, BCHE | DRD2 677/4885DRD3 917/4885DRD1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.